Brainstorm Cell TherapeuticsSTU:GHD 26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Brainstorm Cell Therapeutics ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Brainstorm Cell Therapeutics EBITDA Margin % Related Terms
Brainstorm Cell Therapeutics EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:GHD vs APM, GNPX, CELZ: EBITDA Margin % Comparison
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brainstorm Cell Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics (STU:GHD) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brainstorm Cell Therapeutics and its competitors. According to the industry distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Brainstorm Cell Therapeutics' EBITDA Margin % too high?
Brainstorm Cell Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' EBITDA Margin % compare to APM and GNPX?
According to the Biotechnology industry distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Brainstorm Cell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Brainstorm Cell Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
26GF Score
Get the complete analysis for STU:GHD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:GHD has been successfully added to your 
